![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » VALEANT PHARMA REVEALS SEC'S INFORMAL INQUIRY INTO ITS STOCK OPTION GRANTS, RELEASE OF DATA ON VIRAMIDINE
VALEANT PHARMA REVEALS SEC'S INFORMAL INQUIRY INTO ITS STOCK OPTION GRANTS, RELEASE OF DATA ON VIRAMIDINE
Costa Mesa, California-based Valeant Pharmaceutical International on Monday morning announced that the Securities and Exchange Commission or SEC is conducting an informal inquiry on the events and circumstances surrounding trading of its common stock and the public release of data from its first pivotal Phase 3 trial for Viramidine, a prodrug of ribavirin for the treatment of chronic hepatitis C.
Trading
Markets
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
11Jul
-
18Jul
-
21Oct